Role of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in Management of Obesity

​

This article looks at the effectiveness of GLP-1 receptor agonists for weight loss as a primary or secondary treatment outcome.

 

As a class, GLP-1 receptor agonists have a generally more favourable safety profile than several other antiobesity agents; transient, mild-to-moderate gastrointestinal symptoms were the most frequently reported adverse effects in clinical trials.

 

Read the full article below.